Clinical trial · Observational
The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human
NCT04298502CI-TRIAL-00047439unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observation study to investigate the molecular mechanism of NKG2C+NK cell expansion after HCMV infection
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Leukemia | Acute Leukemia | ONTOLOGY_EXACT | 0.90 |
| CMV Viremia | — | UNRESOLVED | — |
| Hematopoietic Stem Cell Transplantation | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- CMV viremia
- timeFrame
- 2 moths post-transplantation
- description
- CMV-DNA\>1.0x10\^3 cpies/mL
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: 1. AML or MDS or CML or ALL undergoing haploidentical stem cells transplantation 2. No severe organ dysfunction or failure 3. Subjects must be capable of, and willing to provide written informed consent to participate in the study. Subjects unable to provide written informed consent by themselves may be consented through their legal representative. Exclusion Criteria: 1. Participation in another industry-sponsored clinical study where treatment for CMV is already specified by the study protocol. 2. Patients received other adoptive immunotherapy such as donor lymphocyte infusion (DLI), Epstein-Barr virus (EBV)-specific T cells and so on.
References
Publications (0)
Data not yet available
No reference posted for this study.